Immune Related Events Predict the Prognosis of Melanoma(M).
Main Article Content
Abstract
Studies have proved that, CPI has been devised with the aim of enhancing survival rates. At times, the body generates an anti-tumor response that results in the disinhibition of T cell function which leads to inflammatory side effects or IRAE. Consequently, individuals with M who have received CPI therapy may manifest IRAE. Thus, research is warranted to explore the potential advantages of integrating dermatologists into interdisciplinary groups to assess IRAE in patients undergoing treatment with CPI in order to optimize their therapeutic results.
Article Details
References
Dupont R, Bérard E, Puisset F, Comont T, Delord JP, Guimbaud R, Meyer N, Mazieres J, Alric L. The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: A real-life retrospective study. Oncoimmunology. 2020 Jan 1;9(1):1682383.
Gault A, Anderson AE, Plummer R, Stewart C, Pratt AG, Rajan N. Cutaneous immune‐related adverse events in patients with melanoma treated with checkpoint inhibitors. British Journal of Dermatology. 2021 Aug 1;185(2):263-71.
Kennedy LB, Salama AK. A review of immune-mediated adverse events in melanoma. Oncology and Therapy. 2019 Dec;7:101-20.
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine. 2018 Jan 11;378(2):158-68.
Esfahani K, Miller Jr WH. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. New England Journal of Medicine. 2017 May 18;376(20):1989-91.
US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute. 2009 May 28;4(03).
Ibraheim H, Perucha E, Powell N. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. Rheumatology. 2019 Dec 1;58(Supplement_7):vii17-28.
Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PloS one. 2013 Jan 14;8(1):e53745.
Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. European journal of cancer. 2016 Jun 1;60:190-209.
Bottlaender L, Amini‐Adle M, Maucort‐Boulch D, Robinson P, Thomas L, Dalle S. Cutaneous adverse events: a predictor of tumour response under anti‐PD‐1 therapy for metastatic melanoma, a cohort analysis of 189 patients. Journal of the European Academy of Dermatology and Venereology. 2020 Sep;34(9):2096-105.
Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal of the American Academy of Dermatology. 2019 Apr 1;80(4):990-7.
Jaber SH, Cowen EW, Haworth LR, Booher SL, Berman DM, Rosenberg SA, Hwang ST. Skin reactions in a subset of patients with stage IV melanoma treated with anti–cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Archives of dermatology. 2006 Feb 1;142(2):166-72.
Ebia MI, Choi JN. Dermatologic reactions to novel immune checkpoint inhibitors. Current Dermatology Reports. 2018 Dec;7:227-38.
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. American journal of clinical dermatology. 2018 Jun;19(3):345-61.
Nguyen ED, Xue YK, Danesh M, Ameri A, Weng CQ, Klebanov N, Foreman RK, Nazarian RM, Demehri S, Tsao H, Kroshinsky D. A case of nivolumab-induced cutaneous toxicity with multiple morphologies. Dermatopathology. 2020 Aug 11;6(4):255-9.
Ibraheim H, Perucha E, Powell N. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. Rheumatology. 2019 Dec 1;58(Supplement_7):vii17-28.
Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, Carlino MS, Kefford R, Fernandez-Penas P. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. Journal of the American Academy of Dermatology. 2016 Mar 1;74(3):455-61.
Bonigen J, Raynaud-Donzel C, Hureaux J, Kramkimel N, Blom A, Jeudy G, Breton AL, Hubiche T, Bedane C, Legoupil D, Pham-Ledard A. Anti-PD1-induced psoriasis: a study of 21 patients. Journal of the European Academy of Dermatology and Venereology: JEADV. 2017 May;31(5):e254-7.
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. American journal of clinical dermatology. 2018 Jun;19(3):345-61.
Jaber SH, Cowen EW, Haworth LR, Booher SL, Berman DM, Rosenberg SA, Hwang ST. Skin reactions in a subset of patients with stage IV melanoma treated with anti–cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Archives of dermatology. 2006 Feb 1;142(2):166-72.
Ibraheim H, Perucha E, Powell N. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. Rheumatology. 2019 Dec 1;58(Supplement_7):vii17-28.
Nardin C, Jeand'Heur A, Bouiller K, Valnet-Rabier MB, Dresco F, Castagna J, Mareschal A, Carlet C, Nerich V, Limat S, Puzenat E. Vitiligo under anti–programmed cell death-1 therapy is associated with increased survival in melanoma patients. Journal of the American Academy of Dermatology. 2020 Mar 1;82(3):770-2.